Showing results (51-60 of 283) with videos related to
Sort By:
Pageof 29
Plos One|June 26, 2020
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemiaShamia Hoque, Brian J Chen, Martin W Schoen, et al.Thrombosis Research|January 24, 2015
Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative dataKristen M Sanfilippo, Tzu-Fei Wang, Brian F Gage, et al.Cancer Treatment and Research|November 30, 2022
Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug ReactionsMatthew A Taylor, Ashley C Godwin, Shamia Hoque, et al.Drug, Healthcare and Patient Safety|June 25, 2011
Beyond the black box: drug- and device-associated hypersensitivity eventsCharles L Bennett, Olatokunbo S Adegboro, Elizabeth A Calhoun, et al.Cancer Treatment and Research|November 30, 2022
Fluoroquinolone-Associated Disability and Other Fluoroquinolone-Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent YearsCharles L Bennett, Oscar Champigneulle, Andrew Bennett, et al.Expert Opinion on Drug Safety|June 9, 2016
Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting systemDennis W Raisch, John A Rafi, Cheng Chen, et al.Journal of Women'S Health (2002)|February 21, 2014
Selection of contraceptive therapy for patients with thrombophilia: a review of the evidenceWhitney D Maxwell, Merna Jacob, Lisa B Spiryda, et al.Biosimilars (Auckland, New Zealand)|May 16, 2014
Rituximab and biosimilars - equivalence and reciprocityZaina P Qureshi, Jametta S Magwood, Sarveshwari Singh, et al.Cancer Treatment and Research|November 30, 2022
Consequences to Patients, Clinicians, and Manufacturers When Very Serious Adverse Drug Reactions Are Identified (1997-2019): A Qualitative Analysis from the Southern Network on Adverse Reactions (SONAR)Courtney R Lubaczewski, Nancy F Olivieri, William R Hrushesky, et al.Expert Opinion on Drug Safety|November 17, 2022
Fluoroquinolones: old drugs, putative new toxicitiesCecilia Bove, Robert A Baldock, Oscar Champigneulle, et al.Pageof 29